Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Aragon-Ching JB; Jain L; Gulley JL; Arlen PM; Wright JJ; Steinberg SM; Draper D; Venitz J; Jones E; Chen CC; Figg WD; Dahut WL; BJU International, 2009, vol. 103, issue 12, p 1636, ISSN 1464410x. ISBN 1464410x.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef